Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Core Viewpoint - Agios Pharmaceuticals, Inc. is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 trial of Mitapivat in Sickle Cell Disease, which led to a significant drop in stock price [1]. Group 1: Trial Results - On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial, which met one primary endpoint but failed to achieve a statistically significant improvement in the annualized rate of pain crises [1]. - The key secondary endpoint, change from baseline in PROMIS Fatigue, was also not met during the trial [1]. Group 2: Stock Market Reaction - Following the trial results, Agios' stock price fell by $22.33 per share, opening at $23.16 per share [1].